Product
Tiotropium Bromide
4 clinical trials
2 indications
Indication
Chronic Obstructive Pulmonary DiseaseIndication
Asthma in ChildrenClinical trial
A Multicenter, Randomized, Placebo-Controlled, Crossover, Single Dose Study To Demonstrate Clinical Pharmacodynamic Bioequivalence of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)Status: Completed, Estimated PCD: 2023-08-11
Clinical trial
Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot StudyStatus: Recruiting, Estimated PCD: 2024-07-28
Clinical trial
Comparing the Acute Effects of Tiotropium Handihaler With Tiotropium Respimat on the Ventilation Distribution in COPD PatientsStatus: Withdrawn, Estimated PCD: 2024-05-01
Clinical trial
A Single-Center, Open-Label, Randomized, Single-Dose, Two-Period, Two-Sequence, Crossover Trial to Assess the Bioequivalence of Test Product Tiotropium Bromide Inhalation Powder (Strength: 18 mcg) and Reference Product (Spiriva®Handihaler®, Strength: 18 mcg) in Healthy Adult Participants Under Fasting ConditionsStatus: Active (not recruiting), Estimated PCD: 2024-08-01